FYERS
Lincoln Pharmaceuticals601.55
-3.30 (-0.55%)

Lincoln Pharmaceuticals Share Price

601.55-3.30 (-0.55%)
+8.39% past 1 Year

Corporate filings & documents

Announcements

Newspaper Publication for Notice of 32nd Annual General Meeting.
2 weeks ago
Newspaper Publication for Notice of 32nd Annual General Meeting.
2 weeks ago
Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.
2 weeks ago
Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.
2 weeks ago
Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("the SEBI Listing Regulations") we are submitting herewith the Annual Report of the Company along with the Notice of 32nd Annual General Meeting ("AGM") for the Financial Year 2025-2026.
2 weeks ago
Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("the SEBI Listing Regulations") we are submitting herewith the Annual Report of the Company along with the Notice of 32nd Annual General Meeting ("AGM") for the Financial Year 2025-2026.
2 weeks ago
32nd Annual General Meeting ("AGM") of the Members of the Company will be held on Wednesday 30th September 2026 at 11:00 A.M. (IST) through Video Conferencing ("VC")/Other Audio-Visual Means ("OVAM") in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Security and Exchange Board of India. We hereby enclose the Notice of 32nd Annual General Meeting of the Company which is being sent to the members through electronic mode.
2 weeks ago
32nd Annual General Meeting ("AGM") of the Members of the Company will be held on Wednesday 30th September 2026 at 11:00 A.M. (IST) through Video Conferencing ("VC")/Other Audio-Visual Means ("OVAM") in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Security and Exchange Board of India. We hereby enclose the Notice of 32nd Annual General Meeting of the Company which is being sent to the members through electronic mode.
2 weeks ago
The intimation of Book Closure and Record date is as enclosed.
3 weeks ago
The intimation of Book Closure and Record date is as enclosed.
3 weeks ago
Pursuant to Regulation 42 of SEBI (LODR) Regulations 2015 we would like to inform you that the 32nd Annual General Meeting of the Company is scheduled to be held on Wednesday September 30 2026 at 11:00 A.M (IST) through Video Conferencing ("VC") /Other Audio-Visual Means ("OVAM").
3 weeks ago
Pursuant to Regulation 42 of SEBI (LODR) Regulations 2015 we would like to inform you that the 32nd Annual General Meeting of the Company is scheduled to be held on Wednesday September 30 2026 at 11:00 A.M (IST) through Video Conferencing ("VC") /Other Audio-Visual Means ("OVAM").
3 weeks ago
Newspaper Advertisement regarding the 32nd Annual General Meeting of the Company to be held on Wednesday September 30 2026.
3 weeks ago
Newspaper Advertisement regarding the 32nd Annual General Meeting of the Company to be held on Wednesday September 30 2026.
3 weeks ago
We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June 2026.
1 month ago
We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June 2026.
1 month ago
Un-Audited Financial Results For Quarter Ended on 30 June 2026.
1 month ago
Un-Audited Financial Results For Quarter Ended on 30 June 2026.
1 month ago
Un-Audited Financial Results of the Company For the Quarter Ended June 30 2026.
1 month ago
Un-Audited Financial Results of the Company For the Quarter Ended June 30 2026.
1 month ago
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Lincoln Pharmaceuticals Ltd has Informed BSE that the meeting of the Board of Directors of the Company is Scheduled on 13/08/2026 Inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2026.
1 month ago
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Lincoln Pharmaceuticals Ltd has Informed BSE that the meeting of the Board of Directors of the Company is Scheduled on 13/08/2026 Inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2026.
1 month ago
Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 we hereby submit the confirmation certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended June 30 2026.
2 months ago
Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 we hereby submit the confirmation certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended June 30 2026.
2 months ago
Intimation of Trading Window Closure for the Quarter ended June 30 2026.
2 months ago
Intimation of Trading Window Closure for the Quarter ended June 30 2026.
2 months ago
We enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31 2026.
3 months ago
Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31 2026 subject to approval of the members at the ensuing Annual General Meeting of the Company.
3 months ago
Audited Financial Results for the Quarter and Year ended March 31 2026.
3 months ago
Outcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March 2026.
3 months ago
Meeting of the Board of Directors is scheduled to be held on May 28 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares of the Company if any.
4 months ago
Meeting of the Board of Directors is scheduled to be held on May 28 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares of the Company if any.
4 months ago
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2026.
4 months ago
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2026.
4 months ago
Annual Secretarial Compliance Report for the financial year ended March 31 2026.
4 months ago
Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting Audit Transfer and Refund)Rules 2016 and amendments thereof.
4 months ago
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Lincoln Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230GJ1995PLC024288</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2025-26 2026-27</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Trusha Shah</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Darshit Shah</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 05/05/2026<br/><br/></div>
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Lincoln Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1995PLC024288</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: TRUSHA SHAH <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: DARSHIT SHAH <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 16/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Lincoln Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1995PLC024288</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: TRUSHA SHAH <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: DARSHIT SHAH <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 16/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months ago
Pursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended March 31 2026.
5 months ago
Pursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended March 31 2026.
5 months ago
Intimation of Closure of Trading Window.
6 months ago
Pursuant to Regulation of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 we attach herewith transcript of conference call held on February 18 2026. A copy of the same is available on website of the company.
7 months ago
We wish to inform you that the Company participated in investor conference- Call Conference on February 18 2026. No Unpublished Price Sensitive Information (UPSI) was shared / discussed in the meeting with investors.
7 months ago
Intimation of Schedule of earnings conference call to discuss the unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
7 months ago
Intimation of Schedule of earnings conference call to discuss the unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
7 months ago
Newspaper Advertisement with respect to unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended on December 31 2025.
7 months ago
Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31.12.2025.
7 months ago
Outcome of the meeting held today
7 months ago
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31st December 2025 And Other Business if any.
7 months ago

Annual reports

FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Feb 2026
ConcallPresentation
May 2024
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation

Lincoln Pharmaceuticals Ltd Share Price Today

The Lincoln Pharmaceuticals Ltd share price today is ₹628.70. During the trading session, the Lincoln Pharmaceuticals Ltd share price opened at ₹626.80 and recorded an intraday high of ₹632.65 and a low of ₹617.70. Last closing price was ₹620.80. Over the past 52 weeks, the Lincoln Pharmaceuticals Ltd share price has ranged between ₹440.00 and ₹770.00. The current Lincoln Pharmaceuticals Ltd stock price reflects real-time market activity based on executed trades on the exchange.